Dr. D.J.A.R. (Dirk Jan) Moes


  • Hospital Pharmacist  TDM & Toxicology
  • Assistant Professor of Applied Clinical Pharmacometrics
  • Clinical Pharmacologist in training
  • PI research line “Computational modelling of tumor growth and clonal evolution in patients treated with targeted therapies”

Research interest


Pharmacometrics, clinical oncology, renal transplantation, liver transplantation, systems pharmacology, immunosuppressants, monoclonal antibodies, oral oncolytics, pharmacogenetics, therapeutic drug monitoring.


clinical pharmacology, clinical toxicology


Pharmacometrics, Clinical Pharmacology, Clinical Pharmacy, Clinical Toxicology, Bioanalysis, LC-MS/MS.

Research line :  “Computational modelling of tumor growth and clonal evolution in patients treated with targeted therapies”:

Mathematical models has long been used in drug development as an efficient tool to quantitatively characterize, understand, and predict pharmacokinetics (PK), pharmacodynamics (PD) and disease progression. With the help of modelling and simulation,  data-driven decision making in drug development and pharmacotherapy could be rationalized. In the field of oncology, the models that characterize the effects of anti-cancer treatments based on tumor size dynamics, which is typically quantified with measurements of tumor diameter and volume, represent one key class of models applied in cancer pharmacology. Drug resistance is one of the major reasons for patients experiencing treatment failure. Inter- and intra-tumor heterogeneity and evolutionary adaptation to treatment are acknowledged as a major reason for the development of resistance. Monitoring such evolutionary progression using circulating tumor DNA (ctDNA) enables us to study these changes over time. It is also demonstrated that mutations detected in ctDNA representing treatment resistance can be detected long before disease progression occurs. Therefore, on the basis of tumor size dynamic models and the evolution of clones identified using quantitative ctDNA markers computational models can be developed to describe this clonal evolution in oncology and ultimately predict adaptive treatment strategies to prevent treatment resistance and prolong survival.

Professional biosketch

I am a hospital pharmacist laboratory (TDM & Toxicology) and clinical researcher at the department of Clinical Pharmacy and Toxicology of the Leiden University Medical Center. 

My long term goal and strong interest is to optimize pharmacotherapy using pharmacometrics. During my PhD I used different pharmacometric techniques to identify biomarkers to optimize immunosuppressive therapy in renal transplant recipients. The past five years I have continued this work and expanded my work to the field of clinical oncology to improve my skills in pharmacometrics and clinical pharmacology. 

Currently I am focussing my research projects on the of a new research line entitled “Computational modelling of tumor growth and clonal evolution in patients treated with targeted therapies”


Selected publications

  • Yin A, Moes DJAR, van Hasselt JGC, Swen JJ, Guchelaar HJ. A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2019 Oct;8(10):720-737. doi:10.1002/psp4.12450. Epub 2019 Aug 9. Review. PubMed PMID: 31250989; PubMed
  • van der Stoep MYEC, Zwaveling J, Bertaina A, Locatelli F, Guchelaar HJ, Lankester AC, Moes DJAR. Population pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation. Br J Clin Pharmacol. 2019 May 29;. doi: 10.1111/bcp.13995. [Epub ahead of print] PubMed PMID: 31144349
  • Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640. PubMed PMID: 31045868
  • Zwart TC, Gokoel SRM, van der Boog PJM, de Fijter JW, Kweekel DM, Swen JJ, Guchelaar HJ, Moes DJAR. Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. Br J Clin Pharmacol. 2018 Dec;84(12):2889-2902. doi: 10.1111/bcp.13755. Epub 2018 Oct 15. PubMed PMID: 30176064; PubMed Central PMCID: PMC6256056.
  • Ter Heine R, van Erp NP, Guchelaar HJ, de Fijter JW, Reinders MEJ, van Herpen CM, Burger DM, Moes DJAR. A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. Br J Clin Pharmacol. 2018 Jul;84(7):1575-1586. doi: 10.1111/bcp.13591. Epub 2018 May 6. PubMed PMID: 29574974; PubMed Central PMCID: PMC6005589.
  • Moes DJ, Press RR, Ackaert O, Ploeger BA, Bemelman FJ, Diack C, Wessels JA, van der Straaten T, Danhof M, Sanders JS, Homan van der Heide JJ, Guchelaar HJ, de Fijter JW. Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. Br J Clin Pharmacol. 2016 Jul;82(1):227-37. doi: 10.1111/bcp.12946. Epub 2016 May 10. PubMed PMID: 27334415; PubMed Central PMCID: PMC4917801
  • Moes DJ, van der Bent SA, Swen JJ, van der Straaten T, Inderson A, Olofsen E, Verspaget HW, Guchelaar HJ, den Hartigh J, van Hoek B. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol. 2016 Feb;72(2):163-74. doi: 10.1007/s00228-015-1963-3. Epub 2015 Oct 31. PubMed PMID: 26521259; PubMed Central PMCID: PMC4713720.
  • Moes DJ, Press RR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012 Jul 1;51(7):467-80. doi: 10.2165/11599710-000000000-00000. PubMed PMID: 22624503.

All publications


Leids Universitair Medisch Centrum
Gebouw 1
Kamer L-01-025

Albinusdreef 2
2333 ZA Leiden
Tel: +31 71 526 6125

Postzone L0-P
Postbus 9600
2300 RC Leiden

E-mail: D.J.A.R.Moes@lumc.nl